Patents by Inventor Benjamin Whitehurst

Benjamin Whitehurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES
    Publication number: 20260152474
    Abstract: The disclosures herein relate to novel compounds of formula I: and salts thereof, wherein X, Y, A, Ring B, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Application
    Filed: November 7, 2025
    Publication date: June 4, 2026
    Inventors: Nigel Alan SWAIN, Benjamin WHITEHURST, Miles Stuart CONGREVE, Giles Albert BROWN
  • l,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES
    Publication number: 20260125347
    Abstract: The present invention relates to compounds of formula I as prostaglandin E2 receptor 4 (EP4) agonists for use in methods of treatment of gastrointestinal and pulmonary dis-cases or disorders. An exemplary compound is e.g. 4-(2-(2-(3-hydroxy-3-(4?-hydroxy-2?-methyl-[1,1?-biphenyl]-3-yl) propyl)-5-oxopyrazolidin-1-yl)ethyl)benzoic acid (Example 1) Pharmacological data is provided, e.g.
    Type: Application
    Filed: August 2, 2023
    Publication date: May 7, 2026
    Applicant: NXERA PHARMA UK LIMITED
    Inventors: Nigel Alan SWAIN, Benjamin WHITEHURST, Miles Stuart CONGREVE, Giles Albert BROWN
  • PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES
    Publication number: 20260042745
    Abstract: The present invention relates to compounds of formula I as prostaglandin E2 receptor 4 (EP4) agonists for use in methods of treatment of gastrointestinal and pulmonary diseases or disorders. The present disclosure provides exemplary compounds and pharmacological data.
    Type: Application
    Filed: August 2, 2023
    Publication date: February 12, 2026
    Applicant: NXERA PHARMA UK LIMITED
    Inventors: Nigel Alan SWAIN, Benjamin WHITEHURST, Miles Stuart CONGREVE, Giles Albert BROWN
  • PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS
    Publication number: 20260015314
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Application
    Filed: July 14, 2025
    Publication date: January 15, 2026
    Inventors: Miles Stuart Congreve, Nigel Alan Swain, Benjamin Whitehurst
  • Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases
    Patent number: 12492174
    Abstract: The disclosures herein relate to novel compounds of formula I: and salts thereof, wherein X, Y, A, Ring B, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Grant
    Filed: January 31, 2025
    Date of Patent: December 9, 2025
    Assignee: Nxera Pharma UK Limited
    Inventors: Nigel Alan Swain, Benjamin Whitehurst, Miles Stuart Congreve, Giles Albert Brown
  • Prostaglandin EPreceptor antagonist compounds
    Patent number: 12391641
    Abstract: The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: August 19, 2025
    Assignee: Nxera Pharma UK Limitied
    Inventors: Miles Stuart Congreve, Nigel Alan Swain, Benjamin Whitehurst
  • MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES
    Publication number: 20250179036
    Abstract: The disclosures herein relate to novel compounds of formula I: and salts thereof, wherein X, Y, A, Ring B, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Application
    Filed: January 31, 2025
    Publication date: June 5, 2025
    Applicant: NXERA PHARMA UK LIMITED
    Inventors: Nigel Alan SWAIN, Benjamin WHITEHURST, Miles Stuart CONGREVE, Giles Albert BROWN
  • GPR35 Agonist Compounds
    Publication number: 20240254093
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts and any tautomers thereof, wherein X, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR35 receptors.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 1, 2024
    Inventors: Miles Stuart CONGREVE, Nigel Alan SWAIN, Giles Albert BROWN, Benjamin WHITEHURST, Neil John FLANGAN
  • PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS
    Publication number: 20220411364
    Abstract: The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Application
    Filed: October 9, 2020
    Publication date: December 29, 2022
    Inventors: Miles Stuart Congreve, Nigel Alan Swain, Benjamin Whitehurst